Abstract: We describe a case of the pre-emptive use of transcatheter aortic valve replacement in a patient with end-stage ischemic cardiomyopathy and native aortic stenosis/aortic insufficiency as a bridge to left ventricular assist device implantation. The use of this strategy can not only medically optimize patients before left ventricular assist device implantation but also provide a minimally invasive bridge to left ventricular assist device support, avoiding concomitant surgical aortic valve replacement or closure.
D
e novo aortic insufficiency (AI) is a well-described entity after left ventricular assist device (LVAD) implantation. Management options include medical optimization with pump speed adjustment, and in more severe cases, surgical aortic valve repair, replacement, or closure. In more recent years, transcatheter aortic valve replacement (TAVR) has been described in this setting. 1 Given the known complications associated with de novo AI after LVAD placement, pre-existing AI mandates aggressive intervention at the time of LVAD implantation to prevent the known sequelae of malperfusion and heart failure. Conventional treatment involves concomitant AVR at the time of LVAD implantation, with the associated incremental risk, especially in patients with greater preoperative comorbid status. 2 We therefore describe a case of the pre-emptive use of TAVR in a patient with end-stage ischemic cardiomyopathy and native AI/aortic stenosis (AS) as a bridge to LVAD implantation.
CASE REPORT
A 67-year-old man with a history of coronary artery disease status after coronary bypass grafting 15 years ago, subsequent percutaneous coronary intervention, ischemic cardiomyopathy with a baseline ejection fraction of 15% on home dobutamine, and severe AI was transferred to our center with a heart failure exacerbation for inotrope-assisted diuresis.
Right heart catheterization demonstrated a pulmonary artery systolic pressure of 70 mm Hg, a cardiac index of 1.6 L/min per square meter and a pulmonary artery saturation of 49%. A transthoracic echocardiogram (TTE) demonstrated severe AI and moderate to severe AS (mean gradient = 22 mm Hg, aortic valve area = 1.1 cm 2 ) with an ejection fraction of 8%. His condition did not improve despite aggressive medical management and LVAD implantation were recommended as a bridge to transplant. Surgical AVR was considered at the time of LVAD. However, given the presence of AS, the risk of concomitant AVR at the time of LVAD was considered high given his Interagency Registry for Mechanically Assisted Circulatory Support score of 2. The decision was made to proceed with a TAVR before LVAD implantation. Contrast-enhanced multidetector computed tomography was performed preoperatively, which demonstrated an annulus diameter of 27.6 mm by 22.6 mm, an area of 475 mm 2 , and a perimeter of 78.5 mm, measurements appropriate for a 26-mm SAPIEN valve.
Transcatheter aortic valve replacement was performed in a hybrid cardiac catheterization laboratory under general anesthesia. Under fluoroscopic and transesophageal echocardiography guidance, a 26-mm SAPIEN III (Edwards Lifesciences Corp, Irvine, CA USA) valve was deployed via a transfemoral approach (Fig. 1) . Postdeployment transesophageal echocardiography demonstrated a well-functioning prosthesis with no evidence of paravalvular regurgitation. The patient clinically improved and was discharged home on postoperative day 3 with a plan for interval readmission and LVAD implantation. He was ambulating short distances with mild dyspnea. Follow-up TTE demonstrated a trace paravalvular leak and an ejection fraction of 12%.
One month after TAVR, the patient underwent placement of a HeartMate II LVAD (Thoratec, Pleasanton, CA USA). His postoperative course was unremarkable, and he was discharged home on postoperative day 13. At the 6-month follow-up visit, the patient continued to have appropriate exercise tolerance, was New York Heart Association class II, and repeat TTE that demonstrated mild paravalvular regurgitation (Fig. 2) . The patient is currently doing well, awaiting heart transplant.
DISCUSSION
In patients with end-stage heart failure and AI, or in this case, AI and AS, who are in need of mechanical support, severe AI must be addressed at the time of LVAD implantation. Milder degrees of AI pose a surgical dilemma because the progression of pre-existing AI is a known complication that can result in malperfusion and worsening heart failure. 3 Aortic valve closure is an option, but in patients with the potential for recovery, the option of weaning and LVAD explantation is eliminated. Furthermore, any period of device failure can be catastrophic. 4 Bioprosthetic valve replacement at the time of LVAD implantation has been performed with success but can carry significant surgical risk, especially in patients with advanced shock. 2 As described in this report, TAVR can provide an excellent alternative for patients with AI, concomitant AS, and end-stage heart failure who are in need of LVAD support. The less conventional use of TAVR and transcatheter occluder devices for pure AI has been described as well, but in the post-LVAD setting. To our knowledge, this is the only report of TAVR as a bridge to LVAD in a patient with native aortic valve disease.
In the only other similar report of pre-LVAD use of TAVR, a valve-in-valve procedure was used to treat prosthetic AI in a patient on extracorporeal membrane oxygenation before LVAD implantation. 5 The present report is unique in that it (1) suggests the potential feasibility of TAVR as a bridging strategy to LVAD implantation in a patient who otherwise would have required urgent surgical aortic valve repair/LVAD implantation with significantly higher risk of morbidity, but perhaps more poignantly, it (2) demonstrates that after TAVR, there was immediate elimination of AI/AS and rapid hemodynamic recovery, allowing our patient to be medically optimized before LVAD implantation.
In summary, we describe the use of TAVR as a minimally invasive bridge to LVAD implantation for a high-risk patient with previous coronary bypass grafting in cardiogenic shock with end-stage heart failure and severe AI/AS. The use of this technology not only avoids the need for concomitant AVR and its associated risk at the time of LVAD implantation but also allows for medical optimization before LVAD implantation in a more elective setting. 
